Analyst Ratings for Genmab A/S (GMAB)
GMAB Rating Summary
GMAB Price Target Summary
- Highest: $58.00 (Guggenheim)
- Lowest: $30.50 (Goldman Sachs)
- Average: $43.20
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$43.20 (-1.3%)
* Over Last 12-Mos
Rating Score: 7.5 / 10
Percentile Rank: 78%
Avg. $ Target:
$43.20 (-1.3%)
* Over Last 12-Mos
Rating Score: 7.5 / 10
Percentile Rank: 78%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 10/20/2026 | Morgan Stanley | Sean Laaman | New Coverage | Equalweight (N/A) |
42.00 (N/A) |
37.00 (43.79) |
18.35% | Details |
| 10/5/2026 | Leerink | Asthika Goonewardene | New Coverage | Outperform (N/A) |
50.00 (N/A) |
34.75 (43.79) |
26.01% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
